May 24 (Reuters) - Mineralys Therapeutics Inc MLYS.O:
MINERALYS THERAPEUTICS INC - LORUNDROSTAT SHOWS 16.9 MMHG REDUCTION AT WEEK 6, 19.0 MMHG AT WEEK 12
MINERALYS THERAPEUTICS INC - LORUNDROSTAT SAFETY PROFILE SHOWS MODEST, REVERSIBLE EFFECTS ON ELECTROLYTES
MINERALYS THERAPEUTICS INC - TRIAL MET ENDPOINTS WITH SIGNIFICANT BLOOD PRESSURE REDUCTION
Source text: ID:nGNX7SCFDs
Further company coverage: MLYS.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.